124 related articles for article (PubMed ID: 346616)
21. Long-term efficacy of halofenate on serum triglyceride levels.
Aronow WS; Vicario MD; Moorthy K; King J; Vawter M; Papageorge's NP
Curr Ther Res Clin Exp; 1975 Dec; 18(6):855-61. PubMed ID: 813950
[No Abstract] [Full Text] [Related]
22. A one year double blind study of the effect of halofenate and clofibrate in patients with hyperlipoproteinemia.
Rottiers R; van Egmond J
Acta Clin Belg; 1975; 30(5):398-408. PubMed ID: 1221746
[No Abstract] [Full Text] [Related]
23. Effect of halofenate and clofibrate on lipid synthesis in rat adipocytes.
Greenspan MD; Germershausen JI; Mackow R
Biochim Biophys Acta; 1975 Feb; 380(2):190-8. PubMed ID: 1120140
[TBL] [Abstract][Full Text] [Related]
24. Influence of obesity on the relationship between insulin and triglyceride levels in endogenous hypertriglyceridemia.
Bagdade JD; Bierman EL; Porte D
Diabetes; 1971 Oct; 20(10):664-72. PubMed ID: 5110698
[No Abstract] [Full Text] [Related]
25. [Differential diagnosis and differential treatment of carbohydrate tolerance disorders in patients with hyperlipoproteinemia. Behavior of plasma lipids, glucose tolerance, and plasma insulin after glucose load during treatment with clofibrate].
Bruns W; Rjasanowski I; Wulfert P; Michael R; Knospe S; Hildmann W
Endokrinologie; 1974 Nov; 64(1):2-12. PubMed ID: 4466653
[No Abstract] [Full Text] [Related]
26. Comparative study of several hypolipidemic agents related to clofibrate.
Beaumont V; Buxtorf JC; Jacotot B; Beaumont JL
Atherosclerosis; 1974; 20(2):141-53. PubMed ID: 4369878
[No Abstract] [Full Text] [Related]
27. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
[No Abstract] [Full Text] [Related]
28. Effect of halofenate on serum lipids.
Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
[No Abstract] [Full Text] [Related]
29. Lipid, glucose, and insulin interrelationships in normal, prediabetic, and chemical diabetic subjects.
Kyner JL; Levy RI; Soeldner JS; Gleason RE; Fredrickson DS
J Lab Clin Med; 1976 Sep; 88(3):345-58. PubMed ID: 956689
[TBL] [Abstract][Full Text] [Related]
30. [Effect of clofibrate on glucose tolerance and insulin secretion in patients with endogenous hypertriglyceridemia (author's transl)].
Schwandt P; Weisweiler P; Neureuther G; Wilkening J
MMW Munch Med Wochenschr; 1976 Mar; 118(12):351-4. PubMed ID: 177863
[TBL] [Abstract][Full Text] [Related]
31. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
Wolfram G; Keller C; Kilani C; Zöllner N
Verh Dtsch Ges Inn Med; 1973; 79():1291-3. PubMed ID: 4597609
[No Abstract] [Full Text] [Related]
32. Halofenate, serum lipids, and exercise performance in coronary heart disease.
Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
Clin Pharmacol Ther; 1974 Jan; 15(1):67-72. PubMed ID: 4587107
[No Abstract] [Full Text] [Related]
33. Long-term effect of halofenate on serum lipids.
Aronow WS; Vangrow J; Pagano J; Khemka M; Vawter M; Papageorge's NP
Curr Ther Res Clin Exp; 1974 Sep; 16(9):897-903. PubMed ID: 4214664
[No Abstract] [Full Text] [Related]
34. [Plasma levels of triglycerides, cholesterol, non-esterified fatty acids and uric acid, during oral glucose load, in subjects with type II diabetes and diminished glucose tolerance].
Sinagra D; Botta RM; Lo Curzio E; Cerasola GA
Boll Soc Ital Biol Sper; 1982 Aug; 58(15):964-70. PubMed ID: 6751356
[TBL] [Abstract][Full Text] [Related]
35. Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.
Cenedella RJ; Crouthamel WG
J Lipid Res; 1976 Mar; 17(2):156-66. PubMed ID: 1270931
[TBL] [Abstract][Full Text] [Related]
36. The effect of halofenate or halofenate free acid on human, rat and guinea pig platelet aggregation.
Minsker DH; Jordan PT; Kling P; MacMillan A; Hucker HB
Thromb Haemost; 1976 Apr; 35(2):358-63. PubMed ID: 989636
[TBL] [Abstract][Full Text] [Related]
37. Halofenate and clofibrate inhibition of pyruvate dehydrogenase from Fusarium culmorum.
Madhosingh C; Orr W
J Environ Sci Health B; 1985 Apr; 20(2):201-14. PubMed ID: 3998411
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
Schapel GJ; Edwards KD
J Pharmacol Exp Ther; 1975 Jul; 194(1):274-84. PubMed ID: 1171221
[TBL] [Abstract][Full Text] [Related]
39. Effects of clofibrate treatment on arginine-induced insulin secretion in endogenous hypertriglyceridemia.
Fedele D; Tiengo A; Muggeo M; Nosadini R; Crepaldi G
Atherosclerosis; 1976; 25(2-3):191-8. PubMed ID: 1008908
[TBL] [Abstract][Full Text] [Related]
40. Halofenate. Its selection and trial as a primary uricosuric agent.
Bluestone R; Campion D; Klinenberg JR
Arthritis Rheum; 1975; 18(6 Suppl):859-62. PubMed ID: 1106434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
